Allostatin® has been successfully tested against pancreatic cancer in South Korea

Allopharm was the organizer of an international meeting of scientists and entrepreneurs
Show all

In early 2019, a South Korean company received the rights to use the Allostatin® molecule to treat certain types of cancer. By October, pilot studies on the use of injected Allostatin® in combined therapy for pancreatic cancer had been completed, these demonstrated the high effectiveness of the new treatment regimen.
U.S. Patent «Synergistic combination of chemotherapy and peptide for treating cancer» Pending.

Комментарии закрыты.